Physiology of Chemotherapy-Induced Emesis and Antiemetic Therapy

Barnes JH. The physiology and pharmacology of emesis. Mol Aspects Med 1984; 7: 397–508 Laszlo J. Nausea and vomiting as major complications of cancer chemotherapy. Drugs 1983; 25 Suppl. 1: 1–7 Kris MG, Gralla RJ, Clark RA, et al. Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol 1985; 3(10): 1379–84 Martin M, Diaz-Rubio E, Sanchez A, et al. The natural course of emesis after carboplatin treatment. Acta Oncol 1990; 29(5): 593–5 Fetting JH, Grochow LB, Folstein MF, et al. The course of nausea and vomiting after high-dose cyclophosphamide. Cancer Treat Rep 1982; 66: 1487–93 Aapro MS. 5-HT3 receptor antagonists: an overview of their present status and future potential in cancer therapy-induced emesis. Drugs 1991 42(4): 551–68 Borison HL, Wang SC. Physiology and pharmacology of vomiting. Pharmacol Rev 1953; 5: 193–230 Borison HL. Electrical stimulation of the central nervous mechanism for vomiting in the cat. Am J Physiol Proc 1948; 155: 428 Borison HL, Wang SC. Functional localization of central coordinating mechanism for emesis in cat. J Neurophysiol 1949; 12: 305–13 Andrews PLR, Davis CJ. The mechanism of emesis induced by anti-cancer therapies. In Andrews PLR, Sanger GJ, editors. Emesis in anti-cancer therapy: mechanisms and treatment. Chapman and Hall: London, 1993: 113–61 Lang IM. Digestive tract motor correlates of vomiting and nausea. Can J Physiol Pharmacol 1990; 68: 242–53 Lang IM, Sarna SK, Dodds WJ. Pharyngeal, esophageal, and proximal gastric responses associated with vomiting. Am J Physiol 1993; 265: G963–72 Miller AD. Respiratory muscle control during vomiting. Can J Physiol Pharmacol 1990; 68: 237–41 Wang SC, Borison HL. Copper sulphate emesis: a study of afferent pathways from gastrointestinal tract. Am J Physiol 1951; 164: 520–6 Wang SC, Borison HL. A new concept of organization of the central emetic mechanism: recent studies on the sites of action of apomorphine, copper sulfate and cardiac glycosides. Gastroenterology 1952; 22(1): 1–12 Borison HL, Brizzee KR. Morphology of emetic chemoreceptor trigger zone in cat medulla oblongata. Proc Soc Exp Biol Med 1951; 77: 38–42 Carpenter DO. Neural mechanisms of emesis. Can J Physiol Pharmacol 1990; 68: 230–6 Borison HL, McCarthy LE. Neuropharmacology of chemotherapy-induced emesis. Drugs 1983; 25 Suppl. 1: 8–17 McCarthy LE, Borison HL. Cisplatin-induced vomiting eliminated by ablation of the area postrema in cats. Cancer Treat Rep 1984; 68(2): 401–4 Andrews PLR, Davis CJ, Bingham S, et al. The abdominal innervation and the emetic reflex: pathways, pharmacology, and plasticity. Can J Physiol Pharmacol 1990; 68: 325–45 Borison HL, Borison R, McCarthy LE. Role of the area postrema in vomiting and related functions. Fed Proc 1984; 43: 2955–8 Mitchelson F. Pharmacological agents affecting emesis: a review (Pt I). Drugs 1992; 43(3): 295–315 Andrews PLR, Rapeport WG, Sanger GJ. Neuropharmacology of emesis induced by anti-cancer therapy. Trends Pharmacol Sci 1988; 9: 334–41 Higgins GA, Kilpatrick GJ, Bunce KT, et al. 5-HT3 receptors antagonists injected into the area postrema inhibit cisplatininduced emesis in the ferret. Br J Pharmacol 1989; 97: 247–55 Nussey SS, Hawthorn J, Page SR, et al. Responses of plasma oxytocin and arginine vasopressin to nausea induced by apomorphine and ipecacuanha. Clin Endocrinol 1988; 28: 297–304 Rowe JW, Shelton RL, Helderman JH, et al. Influence of the emetic reflex on vasopressin release in man. Kidney Int 1979; 16: 729–35 Fisher RD, Rentschler RE, Nelson JC, et al. Elevation of plasma antidiuretic hormone (ADH) associated with chemotherapy-induced emesis in man. Cancer Treat Rep 1982; 66: 25–9 Edwards CM, Carmichael J, Baylis PH, et al. Arginine vasopressin — a mediator of chemotherapy induced emesis? Br J Cancer 1989; 59: 467–70 Triozzi PL, Laszlo J. Optimum management of nausea and vomiting in cancer chemotherapy. Drugs 1987; 34: 136–49 Cubeddu LX. Mechanisms by which cancer chemotherapeutic drugs induce emesis. Semin Oncol 1992; 19 (6 Suppl. 15): 2–13 Hainsworth JD, Omura GA, Khojasteh A, et al. Ondansetron (GR38032F): a novel antiemetic effective in patients receiving a multiple day regimen of cisplatin chemotherapy. Am J Clin Oncol 1991; 14(4): 336–40 Fox SM, Einhorn LH, Cox E, et al. Ondanseton versus ondansetron, dexamethasone, and chlorpromazine in the prevention of nausea and vomiting associated with multiple-day cisplatin chemotherapy. J Clin Oncol 1993; 11: 2391–5 Harding RK, Hugenholtz H, Keaney M, et al. Discrete lesions of the area postrema abolish radiation-induced emesis in the dog. Neurosci Lett 1985; 53: 95–100 Borison HL, Brand ED, Orkand RK. Emetic action of nitrogen mustard (mechlorethamine hydrochloride) in dogs and cats. Am J Physiol 1958; 192(2): 410–6 Carl PL, Cubeddu LX, Lindley C, et al. Do humoral factors mediate cancer chemotherapy-induced emesis? Drug Metab Rev 1989; 21(2): 319–33 King GL. Animals models in the study of vomiting. Can J Physiol Pharmacol 1990b; 68: 260–8 Peroutka SJ. Chemotherapeutic agents do not interact with neurotransmitter receptors. Cancer Chemother Pharmacol 1987; 19: 131–2 Herrstedt J, Hyttel J, Pedersen J. Interaction of the antiemetic metopimazine and anticancer agents with brain dopamine D2, 5-hydroxytryptamine3, histamine Hi, muscarine cholinergic and α1-adrenergic receptors. Cancer Chemother Pharmacol 1993; 33: 53–6 Costall B, Domeney AM, Naylor RJ, et al. Emesis induced by cisplatin in the ferret as a model for the detection of antiemetic drugs. Neuropharmacology 1987; 26(9): 1321–6 Smith WL, Callaham EM, Alphin RS. The emetic action of centrally administered cisplatin in cats and its antagonism by zacopride. J Pharm Pharmacol 1988; 40: 142–3 Hawthorn J, Ostler KJ, Andrews PLR. The role of the abdominal visceral innervation and 5-hydroxytryptamine M-receptors in vomiting induced by the cytotoxic drugs cyclophosphamide and cis-platin in the ferret. Q J Exp Physiol 1988; 73: 7–21 Harris HL. Cytotoxic-therapy-induced vomiting is mediated via enkephalin pathways. Lancet 1982; I: 714–6 Stewart DJ. Cancer therapy, vomiting, and antiemetics. Can J Physiol Pharmacol 1990; 68: 304–13 Alfieri AB, Cubeddu LX. Effects of inhibition of serotonin synthesis on 5-hydroxyindoleacetic acid excretion, in healthy subjects. J Clin Pharmacol 1994; 34: 153–7 Alfieri AB, Cubeddu LX. Treatment with para-chlorophenyl-alanine antagonises the emetic response and the serotoninreleasing actions of cisplatin in cancer patients. Br J Cancer 1995; 71: 629–32 Barnes NM, Barry JM, Costall B, et al. Antagonism by parachlorophenylalanine of cisplatin-induced emesis [abstract]. Br J Pharmacol 1987; 92: 649P Gunning SJ, Hagan R, Tyers MB. Cisplatin induces biochemical and histological changes in the small intestine of the ferret (abstractl. Br J Pharmacol 1987; 90: 135P Costall B, Domeney AM, Naylor RJ, et al. 5-hydroxytryptamine M-receptor antagonism to prevent cisplatin-induced emesis. Neuropharmacology 1986; 25(8): 959–61 Miner WD, Sanger GJ, Turner DH. Comparison of the effect of BRL 24924, metoclopramide and domperidone on cisplatininduced emesis in the ferret [abstract). Br J Pharmacol 1986; 88: 374P Miner WD, Sanger GJ, Turner DH. Evidence that 5-hydroxytryptamine.3 receptors mediate cytotoxic drug and radiationevoked emesis. Br J Cancer 1987; 56: 159–62 Boyle EA, Miner WD, Sanger GJ. Different anti-cancer therapies evoke emesis by mechanisms that can be blocked by the 5-HT3 receptor antagonist BRL 43694 [abstract!. Br J Pharmacol 1987a; 91 Suppl.: 418P Fukui H, Yamamoto M, Sato S. Vagal afferent fibers and peripheral 5-HT3 receptors mediate cisplatin-induced emesis in dogs. Jpn J Pharmacol 1992; 59: 221–6 Miner WD, Sanger GJ. Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism. Br J Pharmacol 1986; 88: 497–9 Boyle EA, Miner WD, Sanger GJ. Anti-emetic activity of BRL 43694, a novel 5-HT3 receptor antagonist [abstract]. Br J Cancer 1987b; 56: 227 Bermudez J, Boyle EA, Miner WD, et al. The anti-emetic potential of the 5-hydroxytryptamine3 receptor antagonist BRL 43694. Br J Cancer 1988; 58: 644–50 Fukui H, Yamamoto M, Sasaki S, et al. Involvement of 5-HT3 receptors and vagal afferents in copper sulfate- and cisplatin-induced emesis in monkeys. Eur J Pharmacol 1993; 249: 13–8 Andrews PLR, Bailey HE, Hawthorn J, et al. GR38O32F, a novel 5-HT3 receptor antagonist, can abolish emesis induced by cyclophosphamide or radiation in the ferret [abstract]. Br J Pharmacol 1987; 91: 417P Bhandari P, Andrews PLR. Preliminary evidence for the involvement of the putative 5-HT4 receptor in zacopride- and copper sulphate-induced vomiting in the ferret. Eur J Pharmacol 1991; 204: 273–80 Stott JRR, Barnes GR, Wright RJ, et al. The effect on motion sickness and occulomotor function of GR38O32F, a 5-HTyreceptor antagonist with anti-emetic properties. Br J Clin Pharmacol 1989; 27: 147–57 Du Bois A, Kriesinger-Schroeder H, Meerpohl HG. The role of serotonin as a mediator of emesis induced by different stimuli. Support Care Cancer 1995; 3: 285–90 Cubeddu LX, Hoffmann IS, Fuenmayor NT, et al. Efficacy of ondansetron (GR 38O32F) and the role of serotonin in cisplatin-indused nausea and vomiting. N Engl J Med 1990a; 322(12): 810–6 Cubeddu LX, Hoffmann IS, Fuenmayor N. Serotonin and emesis - from animals to humans: a discussion of Professor Naylor’s paper. Br J Cancer 1992a; 66 Suppl. XIX: S9–11 Cubeddu LX, Hoffmann IS, Fuenmayor NT, et al. Changes in serotonin metabolism in cancer patients: its relationship to nausea and vomiting induced by chemotherapeutic drugs. Br J Cancer 1992b; 66: 198–203 Cubeddu LX, O’Connor DT, Hoffmann I, et al. Plasma chromogranin A marks emesis and serotonin release associated with dacarbazine and nitrogen mustard but not with cyclophosphamide. Br J Cancer 1995a; 72: 1033–8 Cubeddu LX, O’Connor DT, Parmer RJ. Plasma chromogranin A: a marker of serotonin release and emesis associated with cisplatin chemotherapy. J Clin Oncol 13 1995b; (3): 681–7 Bargsten G, Grube D. Serotonin storage and chromogranins: an experimental study in rat gastric endocrine cells. J Histochem Cytochem 1992; 40(8): 1147–55 Van Wijngaarden I, Tulp MThM, Soudijn W. The concept of selectivity in 5-HT receptor research. Eur J Pharmacol 1990; 188: 301–12 Fukui H, Yamamoto M, Sasaki S, et al. Possible involvement of 5-HT4 receptors in copper sulfate-induced vomiting in dogs. Eur J Pharmacol 1994; 257: 47–52 Sancilio LF, Pinkus LM, Jackson CB, et al. Emetic activity of zacopride in ferrets and its antagonism by pharmacological agents. Eur J Pharmacol 1990; 181: 303–6 Wynn RL, Essien E, Thut PD. The effects of different antiemetic agents on morphine-induced emesis in ferrets. Eur J Pharmacol 1993; 241: 47–54 Bhandari P, Bingham S, Andrews PLR. The neuropharmacology of loperamide-induced emesis in the ferret: the role of the area postrema, vagus, opiate and 5-HT3 receptors. Neuropharmacology 31 1992; (8): 735–42 Bockaert J, Fozard JR, Dumuis A, et al. The 5-HT4 receptor: a place in the sun. Trends Pharmacol Sei 1992; 13: 141–5 Hoyer D, Clarke DE, Fozard JR, et al. Vllth International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 1994; 46(2): 157–203 Lucot JB. 5-HTia receptor agonists as anti-emetics. In: Reynolds DJM, Andrews PLR, Davis CJ, editors. Serotonin and the scientific basis of anti-emetic therapy. Oxford: Oxford Clinical Communications, 1995: 222–7 Jovanovic-Micic D, Samardzic R, Beleslin DB. The role of ocadrenergic mechanisms within the area postrema in dopamine-induced emesis. Eur J Pharmacol 1995; 272: 21–30 Lawes INC. The origin of the vomiting response: a neuroanatomical hypothesis. Can J Physiol Pharmacol 1990; 68: 254–9 Cubeddu LX, Lindley CM, Wetsel W, et al. Role of angiotensin II and vasopressin in cisplatin-induced emesis. Life Sei 1990b; 46: 699–705 Kucharczyk J, Harding RK. Regulatory peptides and the onset of nausea and vomiting. Can J Physiol Pharmacol 1990; 68: 289–93 McRitchie DA, Törk I. Distribution of substance P-like immunoreactive neurons and terminals throughout the nucleus of the solitary tract in the human brainstem. J Comp Neurol 1994; 343: 83–101 Watson JW, Gonsalves SF, Fossa AA, et al. The anti-emetic effects of CP-99,994 in the ferret and the dog: role of the NK1 receptor. Br J Pharmacol 1995; 115: 84–94 Sundler F, Alumets J, Håkanson R. 5-hydroxytryptamine-containing enterochromaffin cells: storage site of substance P. Acta Physiol Scand 1977; 452: 121–3 Tattersall FD, Rycroft W, Hargreaves RJ, et al. The tachykinine receptor antagonist CP-99,994 attenuates cisplatin induced emesis in the ferret. Eur J Pharmacol 1993; 250: R5–6 Bountra C, Bunce K, Dale T, et al. Anti-emetic profile of a non-peptide neurokinin NK1 receptor antagonist, CP-99,994, in ferrets. Eur J Pharmacol 1993; 249: R3–4 Tattersall FD, Rycroft W, Hill RG, et al. Enantioselective inhibition of apomorphine-induced emesis in the ferret by the neurokinin 1 receptor antagonist CP99,994. Neuropharmacology 1994; 33(2): 259–60 Gardner CJ, Twissel DJ, Dale TJ, et al. The broad-spectrum anti-emetic activity of the novel non-peptide tachykinin NK1 receptor antagonist GR 203040. Br J Pharmacol 1995; 116: 3158–63 Adrian TE, Ferri GL, Bacarese-Hamilton AJ, et al. Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 1985; 89: 1070–7 Harding RK, McDonald TJ. Identification and characterization of the emetic effects of peptide YY. Peptides 1989; 10: 21–4 Perry MR, Rhee J, Smith WL. Plasma levels of peptide YY correlate with cisplatin-induced emesis in dogs. J Pharm Pharmacol 1994; 46: 553–7 Akwari OE. The gastrointestinal tract in chemotherapy-induced emesis: a final common pathway. Drugs 1983; 25 Suppl. I: 18–34 Cubeddu LX, Hoffmann IS. Participation of serotonin on early and delayed emesis induced by initial and subsequent cycles of cisplatinum-based chemotherapy: effects of antiemetics. J Clin Pharmacol 1993; 33: 691–7 Fredrikson M, Hursti TJ, Steineck G, et al. Delayed chemotherapy-induced nausea is augmented by high levels of endogenous noradrenaline. Br J Cancer 1994; 70: 642–5 Sanger G.J. New antiemetic drugs. Can J Physiol Pharmacol 1990; 68: 314–24 Leslie RA, Shah Y, Thejomayen M, et al. The neuropharmacology of emesis: the role of receptors in neuromodulation of nausea and vomiting. Can J Physiol Pharmacol 1990; 68: 279–88 Lang IM, Sarna SK. The role of adrenergic receptors in the initiation of vomiting and its gastrointestinal motor correlates. J Pharmacol Exp Ther 1992; 263(1): 395–403 Craig JB, Powell BL, White DR, et al. Antiemetic therapy in patients treated with high-dose cytosine arabinoside. Oncology 1987; 44: 90–2 Gordon CJ, Pazdur R, Ziccarelli A, et al. Metoclopramide versus metoclopramide and lorazepam. Cancer 1989; 63: 578–82 Maher J. Intravenous lorazepam to prevent nausea and vomiting associated with cancer chemotherapy. Lancet 1981; I: 91–2 Gaddum JH, Picarelli ZP. Two kinds of tryptamine receptor. Br J Pharmacol 1957; 12: 323–8 Richardson BP, Engel G. The pharmacology and function of 5-HT3 receptors. Trends Neurosci 1986; 9: 424–8 Bradley PB, Engel G, Feniuk W, et al. Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacology 1986; 25(6): 563–76 Richardson BP, Engel G, Donatsch P, et al. Identification of serotonin M-receptor subtypes and their specific blockade by a new class of drugs. Nature 1985; 316: 126–31 Tyers MB. Site(s) and mechanisms of the anti-emetic action of 5-HT3 receptor antagonists: a discussion of Professor Naylor’s paper. Br J Cancer 1992a; 66 Suppl. 19: S12–3 Tyers MB. Pharmacology and preclinical antiemetic properties of ondansetron. Semin Oncol 1992b; 19 Suppl. 10: 1–8 Fozard JR. Neuronal 5-HT receptors in the periphery. Neuropharmacology 1984; 23(12B): 1473–86 Cohen ML, Bloomquist W, Gidda JS, et al. Comparison of the 5-HT3 receptor antagonist properties of ICS 205-930, GR 38O32F and zacopride. J Pharmacol Exp Ther 1988; 248(1): 197–201 Higgins GA, Kilpatrick GJ, Bunce KT, et al. 5-HT3 receptors in the area postrema may mediate the anti-emetic effects of 5-HT3 antagonists in the ferret [abstract]. Br J Pharmacol 1988; 95: 504P Butler A, Hill JM, Ireland SJ, et al. Pharmacological properties of GR38032F, a novel antagonist at 5-HT3 receptors. Br J Pharmacol 1988; 94: 397–412 Sanger GJ, Nelson DR. Selective and functional 5-hydroxy-tryptamine3 receptor antagonism by BRL 43694 (granisetron). Eur J Pharmacol 1989; 159: 113–24 Millson D, Sohail S, Lettis S, et al. GR68755, a novel, specific 5-HT3 receptor antagonist: effect on the flare response to intradermal 5-HT in man. Br J Clin Pharmacol 1991; 32: 651P–2P Goldberg MJ, Cerimele BJ. Effect of zatosetron (LY277359), a serotonergic receptor (5-HT3) antagonist, on ipecac-induced emesis in healthy men [abstract]. Clin Pharmacol Ther 1991; 49: 171 Fozard JR, Mobarok Ali ATM. Blockade of neuronal tryptamine receptors by metoclopramide. Eur J Pharmacol 1978; 49: 109–12 Fozard JR. 5-HT3 receptors and cytotoxic drug-induced vomiting. Trends Pharmacol Sci 1987; 8: 44–5 Tyers MB, Freeman AJ. Mechanism of the anti-emetic activity of 5-HT3 receptor antagonists. Oncology 1992; 49: 263–8 Borison HL, Borison R, McCarthy LE. Phylogenic and neurologic aspects of the vomiting process. J Clin Pharmacol 1981; 21: 23S–9S Andrews PLR, Bhandari P. The 5-hydroxytryptamine receptor antagonists as antiemetics: preclinical evaluation and mechanism of action. Eur J Cancer 1993; 29A Suppl. 1: S11–6 Costall B, Domeney AM, Naylor RJ, et al. Fluphenazine, ICS 205-930 and dl-fenfluramine differentially antagonise drug-induced emesis in the ferret. Neuropharmacology 1990; 29(5): 453–62 Schwartz SM, Goldberg J, Gidda JS, et al. Effect of zatosetron on ipecac-induced emesis in dogs and healthy men. J Clin Pharmacol 1994; 34: 250–4 Naylor RJ, Inall FC. The physiology and pharmacology of postoperative nausea and vomiting. Anesthesia 1994; 49 Suppl.: 2–5 Barnes NM, Bunce KT, Naylor RJ, et al. The actions of fentanyl to inhibit drug-induced emesis. Neuropharmacology 1991; 30(10): 1073–83 Wang SC, Glaviano VV. Locus of emetic action of morphine and hydergine in dogs. J Pharmacol Exp Ther 1954; 111: 329–34 King GL. Emesis and defecations induced by 5-hydroxytryptamine (5-HT3) receptor antagonist zacopride in the ferret. J Pharmacol Exp Ther 1990a; 253(3): 1034–41 Middlefell VC, Price TL. 5-HT3 receptor agonism may be responsible for the emetic effects of zacopride in the ferret. Br J Pharmacol 1991; 103: 1011–2 Sancilio LF, Pinkus LM, Jackson CB, et al. Studies on the emetic and antiemetic properties of zacopride and its enantiomers. Eur J Pharmacol 1991; 192: 365–9 Feldberg W, Smith AN. Release of histamine by tryptamine and 5-hydroxytryptamine. Br J Pharmacol 1953; 8: 406–11 Tonnesen P. Intracutaneous and skin prick testing with serotonin and histamine. Allergy 1986; 41: 196–202 Orwin JM, Fozard JR. Blockade of the flare response to intradermal 5-hydroxytryptamine in man by MDL 72.222, a selective antagonist at neuronal 5-hydroxytryptamine receptors. Eur J Pharmacol 1986; 30: 209–12 Arnold BDC, Cooper SM, Rapeport WG. An investigation of 5-hydroxytryptamine induced axon reflex flares in man. Br J Clin Pharmacol 1988; 25: 126P–7P Sohail S, Lettis S, Millson D. Comparison of an autoinjector device with conventional intradermal injection of 5-HT to produce a flare response in man [abstract]. Br J Clin Pharmacol 1991; 32: 662P Heavey DJ, Barnes VF, Orwin J, et al. Inhibition of 5-HT induced axon reflex flares by MDL 72422 [abstract]. Br J Clin Pharmacol 1986; 21 Suppl.: 558P Fowler PA, Sweetland J, Lobo D, et al. The effect of ondansetron on the flare response produced by intradermal 5-HT. Br J Clin Pharmacol 1992; 34: 18IP–2P Cooper SM, Arnold BDC, Rapeport WG. Inhibition of 5-HT induced axon-reflex flares by BRL 43694, a novel 5-HT3 receptor antagonist. Br J Clin Pharmacol 1988; 25: 106P–7P Sweetland J, Lettis S, Fowler PA, et al. Duration of the inhibitory effect of intravenous ondansetron on intradermal 5-HT induced flare [abstract]. Br J Clin Pharmacol 1992; 33: 565P Dunlop DJ, Young F, Soukop M, et al. The inhibition of 5-HT induced axon-reflex flare in patients undergoing treatment with granisetron (Kytril) by prophylaxis and intervention for cancer chemotherapy induced nausea and vomiting [abstract]. Ann Oncol 1990; 1 Suppl.: 110 Radomski JL, Hagan EC, Fuyat HN, et al. The pharmacology of ipecac. J Pharmacol Ther 1952; 104: 421–6 Reynolds JEF, editor. Martindale: the extra pharmacopeia. 30th ed. London: Pharmaceutical Press, 1993 Minton NA, Hla KK, Chilton JE, et al. Ipecacuanha-induced emesis: a potential model for testing the antiemetic activity of 5-HT3 receptor antagonists. Br J Clin Pharmacol 1992; 33: 221P–2P Minton N, Swift R, Lawlor C, et al. Ipecacuanha-induced emesis: a human model for testing antiemetic drug activity. Clin Pharmacol Ther 1993; 54(1): 53–7 Markham A, Sorkin EM. Ondansetron: an update of its therapeutic use in chemotherapy-induced and postoperative nausea and vomiting. Drugs 1993; 45(6): 931–52 Minton NA. Volunteer models for predicting antiemetic activity of 5-HTvreceptor antagonists. Br J Clin Pharmacol 1994; 37: 525–30 Page SR, Peterson DB, Crosby SR, et al. The responses of arginine vasopressin and adrenocorticotrophin to nausea induced by ipecacuanha. Clin Endocrinol 1990; 33(6): 761–70 Marty M, Richard A, d’Aliens H, et al. Effet antiémétique de l’ondansetron au cours de cures répétées de chimiothérapies contenant du cisplatine. Bull Cancerol 1993; 80: 618–23